AKT1 and neurocognition in schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 41, Issue 2, 2007, Pages 169-177

  Pinheiro, Andrea Poyastro ^b,c   Keefe, Richard S E ^d   Skelly, Tara ^b   Olarte, Megan ^b   Leviel, Keren ^b   Lange, Leslie A ^b   Lange, Ethan M ^b   Stroup, T Scott ^b   Lieberman, Jeffrey ^e   Sullivan, Patrick F ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Duke University Medical Center ^*  (United States)

Author keywords

AKT1; Association study; Neurocognition; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; PROTEIN KINASE B;

ADULT; AGED; ALERTNESS; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PATHOGENESIS; PHENOTYPE; PROCESSING; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; VERBAL MEMORY; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; BRAIN; COGNITION DISORDERS; CONTINENTAL POPULATION GROUPS; FEMALE; GENOMICS; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROTO-ONCOGENE PROTEINS C-AKT; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34248168791     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670601109956     Document Type: Article

References (36)

1. Grimes, CA and Jope, RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol, 65, pp. 391-426.
2. Beaulieu, JM, Sotnikova, TD, Marion, S., Lefkowitz, RJ, Gainetdinov, RR and Caron, MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell, 122, pp. 261-273.
3. Emamian, ES, Hall, D., Birnbaum, MJ, Karayiorgou, M. and Gogos, JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet, 36:2, pp. 131-137.
4. Ikeda, M., Iwata, N. and Suzuki, T. (2004) Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry, 56, pp. 698-700.
5. Ohtsuki, T., Inada, T. and Arinami, T. (2004) Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population. Mol Psychiatry, 9, pp. 981-983.
6. Schwab, SG, Hoefgen, B. and Hanses, C. (2005) Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry, 58, pp. 446-450.
7. Liu, YL, Fann, CS and Liu, CM (2006) Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population. Psychiatr Genet, 16, pp. 39-41.
8. Gottesman, II and Gould, TD (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry, 160, pp. 636-645.
9. Green, MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry, 153, pp. 321-330.
10. Hoff, AL, Riordan, H., O'Donnell, DW, Morris, L. and DeLisi, LE (1992) Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry, 149, pp. 898-903.
11. Saykin, AJ, Shtasel, DL and Gur, RE (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry, 51, pp. 124-131.
12. Bilder, RM, Goldman, RS and Robinson, D. (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry, 157, pp. 549-559.
13. Lin, CH, Yeh, SH, Lu, KT, Leu, TH, Chang, WC and Gean, PW (2001) A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron, 31, pp. 841-851.
14. Mizuno, M., Yamada, K. and Takei, N. (2003) Phosphatidylinositol 3-kinase: A molecule mediating BDNF-dependent spatial memory formation. Mol Psychiatry, 8, pp. 217-224.
15. Lieberman, JA, Stroup, TS and McEvoy, JP (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, pp. 1209-1223.
16. Stroup, TS, McEvoy, JP and Swartz, MS (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull, 29, pp. 15-31.
17. First, M., Spitzer, R., Gibbon, M. and Williams, J. (1994) Structured Clinical Interview for DSM-IV Axis I Disorders-administration booklet, American Psychiatric Press, Washington, DC
18. American Psychiatric Association (1994) diagnostic and statistical manual of mental disorders, American Psychiatric Association, Washington, DC
19. Livak, KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal, 14, pp. 143-149.
20. Chen, X. and Sullivan, PF (2003) Single nucleotide polymorphism genotyping: Biochemistry, protocol, cost, and throughput. Pharmacogenom J, 3, pp. 77-96.
21. Keefe, RS, Mohs, RC and Bilder, RM (2003) Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale. Schizophr Bull, 29, pp. 45-55.
22. Keefe, RS, Bilder, RM and Harvey, PD (2006) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31, pp. 2033-2046.
23. Barrett, JC, Fry, B., Maller, J. and Daly, MJ (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, pp. 263-265.
24. Risch, NJ (2000) Searching for genetic determinants in the new millennium. Nature, 405, pp. 847-856.
25. Sullivan, PF, Eaves, LJ, Kendler, KS and Neale, MC (2001) Genetic case-control association studies in neuropsychiatry. Arch Gen Psychiatry, 58, pp. 1015-1024.
26. Wacholder, S., Rothman, N. and Caporaso, N. (2000) Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J Natl Cancer Inst, 92, pp. 1151-1158.
27. Devlin, B. and Roeder, K. (1999) Genomic control for association studies. Biometrics, 55, pp. 997-1004.
28. Freedman, ML, Reich, D. and Penney, KL (2004) Assessing the impact of population stratification on genetic association studies. Nat Genet, 36, pp. 388-393.
29. Heiman, GA, Hodge, SE, Gorroochurn, P., Zhang, J. and Greenberg, DA (2004) Effect of population stratification on case-control association studies. I Elevation in false positive rates and comparison to confounding risk ratios (a simulation study). Hum Hered, 58, pp. 30-39.
30. Gorroochurn, P., Hodge, SE, Heiman, G. and Greenberg, DA (2004) Effect of population stratification on case-control association studies. II. False-positive rates and their limiting behavior as number of subpopulations increases. Hum Hered, 58, pp. 40-48.
31. Shields, AE, Fortun, M. and Hammonds, EM (2005) The use of race variables in genetic studies of complex traits and the goal of reducing health disparities. Am Psychologist, 60, pp. 77-103.
32. (2004) Foundation for Statistical Computing, Foundation for Statistical Computing, Vienna, Austria
33. Schaid, DJ, Rowland, CM, Tines, DE, Jacobson, RM and Poland, GA. (2002) Score tests for association between traits and haplolypes when linkage phase is ambiguous. Am J Hum Genet, 70, pp. 425-434.
34. Colhoun, HM, McKeigue, PM and Smith, G Davey (2003) Problems of reporting genetic associations with complex outcomes. Lancet, 361:9360, pp. 865-872.
35. Little, J., Bradley, L. and Bray, MS (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol, 156, pp. 300-310.
36. Elvevag, B. and Goldberg, TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol, 14, pp. 1-21.